AWH vs. ICCC, OCX, ABIO, CDIO, TRIB, BMRA, VNRX, TKNO, LIAN, and GBS
Should you be buying Aspira Women's Health stock or one of its competitors? The main competitors of Aspira Women's Health include ImmuCell (ICCC), OncoCyte (OCX), ARCA biopharma (ABIO), Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), VolitionRx (VNRX), Alpha Teknova (TKNO), LianBio (LIAN), and GBS (GBS). These companies are all part of the "medical" sector.
ImmuCell (NASDAQ:ICCC) and Aspira Women's Health (NASDAQ:AWH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
Aspira Women's Health has a consensus price target of $4.45, indicating a potential upside of 100.45%. Given ImmuCell's higher possible upside, analysts plainly believe Aspira Women's Health is more favorable than ImmuCell.
In the previous week, Aspira Women's Health had 1 more articles in the media than ImmuCell. MarketBeat recorded 4 mentions for Aspira Women's Health and 3 mentions for ImmuCell. Aspira Women's Health's average media sentiment score of 1.59 beat ImmuCell's score of -0.27 indicating that ImmuCell is being referred to more favorably in the media.
ImmuCell has a net margin of -18.31% compared to ImmuCell's net margin of -163.95%. Aspira Women's Health's return on equity of -15.21% beat ImmuCell's return on equity.
13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 12.2% of Aspira Women's Health shares are owned by institutional investors. 6.6% of ImmuCell shares are owned by company insiders. Comparatively, 4.3% of Aspira Women's Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ImmuCell has higher revenue and earnings than Aspira Women's Health. ImmuCell is trading at a lower price-to-earnings ratio than Aspira Women's Health, indicating that it is currently the more affordable of the two stocks.
ImmuCell received 108 more outperform votes than Aspira Women's Health when rated by MarketBeat users. Likewise, 73.33% of users gave ImmuCell an outperform vote while only 27.08% of users gave Aspira Women's Health an outperform vote.
ImmuCell has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Aspira Women's Health has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.
Summary
ImmuCell beats Aspira Women's Health on 11 of the 17 factors compared between the two stocks.
Get Aspira Women's Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for AWH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AWH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aspira Women's Health Competitors List
Related Companies and Tools
